恩考芬尼
Tier C — Watch / tradeEncorafenib · all drugs expiring in 2030 →
Targets：B-raf
Brand：BRAFTOVI、Braftovi、毕太维
Indications (approved)：非小细胞肺癌、结直肠癌、甲状腺瘤、黑色素瘤
Regional status
Synthetic routes & intermediates1 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| ENCO-001 | 100-52-7Available | benzaldehyde |
| ENCO-002 | 16726-41-3 | isopropylhydrazine hydrochloride |
| ENCO-003 | 1086271-92-2 | (E)-1-benzylidene-2-isopropylhydrazine |
| ENCO-004 | 123-06-8 | 2-(ethoxymethylene)malononitrile |
| ENCO-005 | 1086250-41-0 | (E)-2-((2-benzylidene-1-isopropylhydrazinyl)methylene)malononitrile |
| ENCO-006 | 89897-29-0 | 3-amino-1-isopropyl-1H-pyrazole-4-carbonitrile |
| ENCO-007 | 1269440-48-3 | 1-(3-amino-1-isopropyl-1H-pyrazol-4-yl)ethan-1-one |
| ENCO-008 | 1269440-49-4 | 1-(3-iodo-1-isopropyl-1H-pyrazol-4-yl)ethan-1-one |
| ENCO-009 | 1269440-51-8 | (Z)-3-(dimethylamino)-1-(3-iodo-1-isopropyl-1H-pyrazol-4-yl)prop-2-en-1-one |
| ENCO-010 | 50-01-1 | guanidine hydrochloride |
| ENCO-011 | 1269440-54-1 | 4-(3-iodo-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-amine |
| ENCO-012 | 1269440-57-4 | 4-(3-iodo-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-ol |
| ENCO-013 | 1269440-58-5 | 2-chloro-4-(3-iodo-1-isopropyl-1H-pyrazol-4-yl)pyrimidine |
| ENCO-014 | 1229025-32-4 | methyl (S)-(1-aminopropan-2-yl)carbamate hydrochloride |
| ENCO-015 | 1269440-60-9 | methyl (S)-(1-((4-(3-iodo-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate |
| ENCO-016 | 1269440-69-8 | tert-butyl (5-chloro-2-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)carbamate |
| ENCO-017 | 1269440-77-8 | methyl (S)-(1-((4-(3-(3-((tert-butoxycarbonyl)amino)-5-chloro-2-fluorophenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate |
| ENCO-018 | 1269440-78-9 | methyl (S)-(1-((4-(3-(3-amino-5-chloro-2-fluorophenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate |
| ENCO-019 | 1269440-99-4 | methyl (S)-(1-((4-(3-(5-chloro-2-fluoro-3-(N-(methylsulfonyl)methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate |
| ENCO-020 | 1996-30-1 | 2-bromo-4-chloro-1-fluorobenzene |
| ENCO-021 | 1269232-93-0 | 3-bromo-5-chloro-2-fluorobenzoic acid |
| ENCO-022 | 1269232-94-1 | tert-butyl (3-bromo-5-chloro-2-fluorophenyl)carbamate |
| ENCO-023 | 73183-34-3Available | 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) |
Frequently asked questions
What are the approved indications of Encorafenib?
Approved indications include: 非小细胞肺癌, 结直肠癌, 甲状腺瘤, 黑色素瘤.
When does the Encorafenib patent expire?
Based on public sources, the Encorafenib patent expires in 2030.
How many synthesis routes are recorded for Encorafenib?
1 synthesis routes are recorded; the shortest is 17 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Encorafenib intermediates?
2 intermediate CAS of Encorafenib are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Encorafenib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24